@Elisabeth_Turner

@DominicS I totally agree with what that article is saying. At the moment there is way too much compartmentalising (is that a word) of the condition when really it is just an inflammatory disease that is progressive from the start. How it presents itself depends on so many factors, including where the inflammation occurs and how much reserve the patient has to compensate for the inflammation. I also totally agree with this - "That is because neurologists, first and foremost, view MS as a physically disabling disease rather than a cognitively disabling disease. This needs to change; #ThinkCognition. "

@DominicS

@elisabeth_turner - Compartmentalising is most definitely a word! I have heard it speculated that the segmentation happen much further back and was, in part, driven by drug companies trying to find niches in which they could show efficacy for their drugs. Given the prevalence of MS and what is charged iselling a drug, any drug, can be quite lucrative and worth the effort, time and expense of using the Key Opinion leaders of the time to help make this compartmentalised view of the condition the norm. The CRAB drugs absolutely rely on this as they are reasonably ineffective at the best of times, and show little or no therapeutic effect on many parts of the spectrum of MS.